Search
Calcitonin gene-related peptide
go.drugbank.com/drugs/DB06379InvestigationalAs a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties … The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin.
Streptococcus pneumoniae type 4 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10322ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOREravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLevobetaxolol
go.drugbank.com/drugs/DB09351ApprovedIt was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued. … Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesCilomilast
go.drugbank.com/drugs/DB03849InvestigationalCilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). … It is orally active and acts as a selective Phosphodiesterase-4 inhibitor.
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnIt is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Products: Xigris (5mg/vial)Defibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIn the USA it is was approved in March, 2016 as Defitelio. … It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects).
Huperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnThe botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. … It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.